University Teaching Hospital, Department of Pathology & Microbiology, Virology Laboratory, Lusaka, Zambia.
University Teaching Hospital, Department of Pediatrics' and Child Health, Lusaka, Zambia.
Vaccine. 2018 Nov 12;36(47):7243-7247. doi: 10.1016/j.vaccine.2018.03.035. Epub 2018 Jun 12.
Following the introduction of rotavirus vaccine into the routine immunization schedule, the burden of rotavirus disease has significantly reduced in Zambia. Although rotavirus vaccines appear to confer good cross-protection against both vaccine and non-vaccine strains, concerns about strain replacement following vaccine implementation remain. We describe the diversity of the circulating rotavirus strains before and after the Rotarix® vaccine was introduced in Lusaka from January 2012.
Under five children were enrolled through active surveillance at University Teaching Hospital using a standardized WHO case investigation form. Stool samples were collected from children who presented with ≥3 loose stool in 24 h and were admitted to the hospital for acute gastroenteritis as a primary illness. Samples were tested for group A rotavirus antigen enzyme-linked immunosorbent assay. Randomly selected rotavirus positive samples were analysed by reverse transcription polymerase chain reaction for G and P genotyping and and Nucleotide sequencing was used to confirm some mixed infections.
A total of 4150 cases were enrolled and stool samples were collected from 4066 (98%) children between 2008 and 2011, before the vaccine was introduced. Rotavirus antigen was detected in 1561/4066 (38%). After vaccine introduction (2012 to 2015), 3168 cases were enrolled, 3092 (98%) samples were collected, and 977/3092 (32%) were positive for rotavirus. The most common G and P genotype combinations before vaccine introduction were G1P[8] (49%) in 2008; G12P[6] (24%) and G9P[8] (22%) in 2009; mixed rotavirus infections (32%) and G9P[8] (20%) in 2010, and G1P[6] (46%), G9P[6] (16%) and mixed infections (20%) in 2011. The predominant strains after vaccine introduction were G1P[8] (25%), G2P[4] (28%) and G2P[6] (23%) in 2012; G2P[4] (36%) and G2P[6] (44%) in 2013; G1P[8] (43%), G2P[4] (9%), and G2P[6] (24%) in 2014, while G2P[4] (54%) and G2P[6] (20%) continued to circulate in 2015.
These continual changes in the predominant strains suggest natural secular variation in circulating rotavirus strains post-vaccine introduction. These findings highlight the need for ongoing surveillance to continue monitoring how vaccine use affects strain evolution over a longer period of time and assess any normal seasonal fluctuations of the rotavirus strains.
轮状病毒疫苗引入常规免疫计划后,赞比亚的轮状病毒疾病负担显著降低。尽管轮状病毒疫苗似乎对疫苗和非疫苗株都有很好的交叉保护作用,但人们仍然担心疫苗实施后会出现菌株替代的问题。我们描述了 2012 年 1 月罗特利克斯 ® 疫苗在卢萨卡引入前后循环轮状病毒株的多样性。
在卢萨卡教学医院,通过使用标准化的世卫组织病例调查表格,对 5 岁以下儿童进行主动监测。从出现 24 小时内≥3 次稀便并因急性胃肠炎作为主要疾病住院的儿童中采集粪便样本。使用酶联免疫吸附试验检测粪便样本中的轮状病毒抗原。对随机选择的轮状病毒阳性样本进行 G 和 P 基因分型的逆转录聚合酶链反应分析,并使用核苷酸测序来确认一些混合感染。
共纳入 4150 例病例,2008 年至 2011 年疫苗引入前收集了 4066 例(98%)儿童的粪便样本。在 4066 例儿童中,1561 例(38%)检测到轮状病毒抗原。疫苗引入后(2012 年至 2015 年),共纳入 3168 例病例,采集了 3092 例(98%)样本,977 例(32%)为轮状病毒阳性。疫苗引入前最常见的 G 和 P 基因型组合为 2008 年 G1P[8](49%);2009 年 G12P[6](24%)和 G9P[8](22%);2010 年混合轮状病毒感染(32%)和 G9P[8](20%);2011 年 G1P[6](46%)、G9P[6](16%)和混合感染(20%)。疫苗引入后,2012 年主要流行株为 G1P[8](25%)、G2P[4](28%)和 G2P[6](23%);2013 年为 G2P[4](36%)和 G2P[6](44%);2014 年为 G1P[8](43%)、G2P[4](9%)和 G2P[6](24%),而 2015 年 G2P[4](54%)和 G2P[6](20%)继续流行。
这些主要流行株的持续变化表明疫苗引入后循环轮状病毒株发生了自然的季节性变化。这些发现强调需要进行持续监测,以继续监测疫苗使用如何在较长时间内影响菌株进化,并评估轮状病毒株的任何正常季节性波动。